Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Triple asterisks denote omissions. COLLABORATION AGREEMENTCollaboration Agreement • August 2nd, 2013 • Macrogenics Inc • Pharmaceutical preparations
*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission.
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Triple asterisks denote omissions. RESEARCH COLLABORATION AND LICENSE AGREEMENT BY AND BETWEEN PFIZER INC. AND MACROGENICS, INC. OCTOBER [—], 2010Research Collaboration and License Agreement • August 2nd, 2013 • Macrogenics Inc • Pharmaceutical preparations
This Research Collaboration and License Agreement (the “Agreement”) is entered into as of October [—], 2010 (the “Effective Date”), by and among Pfizer, Inc., a corporation organized and existing under the laws of the State of Delaware and having a place of business at 500 Arcola Road, Collegeville, Pennsylvania 19426, United States (“Pfizer”) and MacroGenics, Inc., a corporation organized and existing under the laws of the State of Delaware and having a place of business at 1500 East Gude Drive, Rockville, MD 20850 (“MacroGenics”). Pfizer and MacroGenics may each be referred to herein individually as a “Party” and collectively as the “Parties.”
LEASE AGREEMENTLease Agreement • August 2nd, 2013 • Macrogenics Inc • Pharmaceutical preparations
THIS LEASE AGREEMENT, made this 2nd day of December 2004, by and between W. M. RICKMAN CONSTRUCTION CO. LLC (“LANDLORD”) and MACRO GENICS, INC. (“TENANT”).
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Triple asterisks denote omissions. LICENSE AGREEMENT BY AND BETWEEN MACROGENICS, INC. AND GILEAD SCIENCES, INC.License Agreement • August 2nd, 2013 • Macrogenics Inc • Pharmaceutical preparations
This License Agreement (this “Agreement”) is entered into and made effective as of the 3rd day of January, 2013 (the “Effective Date”), by and between MacroGenics, Inc., a corporation organized and existing under the laws of the State of Delaware, having a principal office located at 9640 Medical Center Drive, Rockville, MD 20850, USA (“MacroGenics”), and Gilead Sciences, Inc., a company organized and existing under the laws of the State of Delaware, having a principal office located at 333 Lakeside Drive, Foster City, CA 94404 (“Gilead”). MacroGenics and Gilead are each referred to herein by name or as a “Party” or, collectively, as “Parties.”
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Triple asterisks denote omissions. AMENDMENTMacrogenics Inc • August 2nd, 2013 • Pharmaceutical preparations
THIS SECOND AMENDMENT (the “Second Amendment”) entered into on the date of last signature to this Amendment by and between MacroGenics, Inc. a Delaware corporation having a place of business at 9640 Medical Center Drive, Rockville, MD 20850 (“MacroGenics”) and Green Cross Corp., having a business office at 303 Bojeong-Dong, Giheung-Gu, Yongin, 446-770, Korea (hereinafter “Green Cross”).
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Triple asterisks denote omissions. Amendment No. 1 to Agreement (“Amendment No. 1”) Date: August 9, 2012Agreement • August 2nd, 2013 • Macrogenics Inc • Pharmaceutical preparations
WHEREAS, the parties hereto desire to amend, among other things, certain terms of the Agreement including increasing, by 1 month, the time allowed for Target Substitution.
Macrogenics, Inc. Amendment to Lease AgreementAmendment to Lease Agreement • August 2nd, 2013 • Macrogenics Inc • Pharmaceutical preparations
This Amendment to Lease Agreement (“AGREEMENT”) made and entered into this 26th day of March 2013, by and between RED GATE III LLC (“LANDLORD”) and MACROGENICS, INC. (“TENANT”).
